Melanocortin agonists: the drugs and peptides that switch the system on

Every one of these molecules is a way of speaking the system's oldest word back to it — the signal to colour, to feed, to calm — only louder, or longer, or on purpose.

Nearly every drug built on this system does one of two things: it switches a melanocortin receptor on, or it blocks it. The ones that switch it on are the agonists — and they are the larger, busier half of the field, because turning this system on is how you build protective pigment, quiet an over-eager appetite, or answer a specific broken signal. This is the map of them: the ones the body makes, the three that are approved, and the pipeline pushing behind them.^[1]

What "agonist" means here

An agonist binds a receptor and activates it; an antagonist binds and blocks it, so the natural signal cannot get through; and an inverse agonist — like the hunger peptide AgRP — pushes the receptor below even its resting activity. The melanocortin receptors are G-protein-coupled receptors that raise the second messenger cAMP when switched on, so a melanocortin agonist is, mechanically, anything that reliably drives that cAMP signal.^[1] A full agonist can push the receptor to its maximum; a partial agonist activates it only part-way even when fully bound — a distinction that matters when the goal is a measured effect rather than a maximal one.

The body makes its own

Before any drug, there were the natural agonists — the peptides cut from the precursor POMC.^[2] The prototype is α-MSH, a broad signal that activates four of the five receptors (MC1R, MC3R, MC4R and MC5R) and sets the template every synthetic agonist is built to copy. ACTH is the specialist: the one POMC peptide that activates MC2R, the adrenal receptor no other melanocortin will touch. β-MSH and γ-MSH round out the set, γ-MSH being the unusually MC3R-preferring one. Every one of these is an agonist; the drugs are simply more durable, sometimes more targeted, impersonations of them.

The three approved agonists

Three melanocortin agonists have cleared the FDA, and they map cleanly onto the receptor each one is aimed at:

• Afamelanotide (Scenesse) — an α-MSH-like peptide that activates MC1R to build protective pigment, approved in 2019 for the rare light-sensitivity disease erythropoietic protoporphyria.^[3]
• Setmelanotide (Imcivree) — an MC4R agonist approved in 2020 for obesity caused by specific genetic breaks in the appetite circuit, and since extended to acquired hypothalamic obesity.^[4]
• Bremelanotide (Vyleesi) — also an MC4R agonist, but developed for a different arm of MC4R biology: low sexual desire in premenopausal women, approved in 2019.^[5]

MC4R agonist drugs

The most active area by far is MC4R agonist drugs. Switching on MC4R signals fullness and reduces food intake, so the receptor has become a target for obesity — especially the forms of obesity driven by a broken melanocortin signal, where restoring MC4R activity treats the actual cause rather than the symptom.^[6]Setmelanotide proved the principle by injection; the race now is to do it orally and more selectively.

Bivamelagon is the one to watch: an oral small molecule that posted clinically meaningful weight loss in a placebo-controlled Phase 2 in acquired hypothalamic obesity, and is now heading for Phase 3.^[7] The broader shift the table shows — from injected peptides toward oral small molecules — is the direction the whole frontier is moving. For where the GLP-1 drugs plug into this same circuit, see GLP-1 & appetite.

MC1R agonists — the pigment side

The other well-populated column targets MC1R, the pigment receptor. Afamelanotide is the approved peptide; dersimelagon is an investigational oral small molecule chasing the same target as a once-daily pill; and the grey-market Melanotan II is a broad agonist used for cosmetic tanning with none of the oversight. All three raise eumelanin by switching MC1R on — the same mechanism, put to very different uses.

Why most agonists aren't selective

It is tempting to picture each of these drugs hitting one receptor cleanly. Most do not. The natural template α-MSH activates four of the five receptors, and most synthetic agonists inherit that breadth — which is exactly why the side effects come bundled with the intended effect. Setmelanotide is developed for MC4R, yet it grips the pigment receptor MC1R almost as tightly, so skin darkening is one of its most common effects.^[4] Genuine selectivity is an engineering achievement, not a default: the next-generation agonist RM-718 is being designed specifically to spare MC1R and avoid the tan. For the receptor-by-receptor numbers behind these claims — how tightly each agonist actually holds each receptor — see the binding matrix.

The honest bottom line

Melanocortin agonists are the on-switches of this system, and the story of the last few years is that we have gone from copying α-MSH crudely to steering it: three approved drugs, a deep pipeline, and a clear engineering goal of making these agonists oral and receptor-selective at once. The counterpart story — the drugs and research tools that turn the system off — runs through the MC4R antagonists. Both together are the field of melanocortin therapeutics.

Common questions

What is a melanocortin agonist?+

A melanocortin agonist is a molecule that switches on one or more of the five melanocortin receptors (MC1R–MC5R), copying what the body’s own α-MSH and ACTH do. Depending on which receptor it activates, that can mean building skin pigment, curbing appetite, triggering sexual arousal, or calming inflammation. It is the opposite of a melanocortin antagonist, which blocks the receptor instead.

What is an MC4R agonist?+

An MC4R agonist activates the melanocortin-4 receptor, the brain’s master switch for appetite and body weight. Switching MC4R on signals fullness and reduces food intake, which is why MC4R agonists are being developed as obesity drugs. Setmelanotide is the approved example; bremelanotide is an MC4R agonist used instead for sexual desire; and oral candidates such as bivamelagon are in trials.

What melanocortin agonists are FDA-approved?+

Three: afamelanotide (Scenesse), an MC1R agonist for the light-sensitivity disease EPP; setmelanotide (Imcivree), an MC4R agonist for certain rare genetic and hypothalamic obesities; and bremelanotide (Vyleesi), an MC4R agonist for low sexual desire in premenopausal women. All three are injected or implanted, because they are peptides.

Are melanocortin agonists selective for one receptor?+

Usually not. The natural signal α-MSH activates four of the five receptors, and most synthetic agonists are similarly broad — which is why a drug aimed at weight or desire can still darken the skin. Genuine receptor selectivity has to be engineered, and even setmelanotide grips the pigment receptor MC1R almost as tightly as its MC4R target.

What is the difference between an agonist and an antagonist?+

An agonist turns a receptor on; an antagonist blocks it so the natural activator cannot. At MC4R, setmelanotide (agonist) signals fullness, while AgRP and the research compound SHU9119 (antagonists) do the reverse and drive hunger. Some blockers go further still: AgRP is an inverse agonist, pushing the receptor below its resting activity.

References

1. 1.Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev. 27(7):736–49. 2006. link ↗
2. 2.Harno E, Gali Ramamoorthy T, Coll AP, White A. POMC: The Physiological Power of Hormone Processing. Physiol Rev. 98(4):2381–2430. 2018. link ↗
3. 3.US FDA. SCENESSE (afamelanotide) implant, for subcutaneous use — prescribing information. FDA label (NDA 210797) — mechanism, indication, and dosing. 2019. link ↗
4. 4.US FDA. FDA approves first treatment for weight management for people with certain rare genetic conditions. News release (setmelanotide / IMCIVREE). 2020. link ↗
5. 5.US FDA / DailyMed. VYLEESI (bremelanotide injection) prescribing information. Label, NDA 210557. 2019. link ↗
6. 6.Clément K, van den Akker E, Argente J, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. PMID 33137293. 2020. link ↗
7. 7.Rhythm Pharmaceuticals. Oral MC4R agonist bivamelagon achieved statistically significant, clinically meaningful BMI reductions in a placebo-controlled Phase 2 trial in acquired hypothalamic obesity. Press release — SIGNAL Phase 2 topline. 2025. link ↗